However, to the best of our knowledge, no other postmarketing studies for rivaroxaban or apixaban for the comparison of the results have been conducted (this includes other indications for direct oral factor Xa inhibition, such as venous thromboembolic disease). This evidence concerns the gene F10 and venous thromboembolism.